| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_28ad23e752cf3d1a9bd9c35ecf2a5018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6267423dbf5278a615914354092dcc0e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-564
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57423
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2015-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79adbe482465c8fec1b012ba7e81cd1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5aa30e973c116bb90faee3445a6718c9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c9526678b58ca63a492addae20168cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38d89425316998fcd2d9bf6481d163b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72448bed65e370874364ccdb11f38985 |
| publicationDate |
2017-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3162803-A2 |
| titleOfInvention |
New compound for inhibiting binding between dx2 protein and p14/arf protein, and pharmaceutical composition for treating or preventing cancer disease containing same as effective ingredient |
| abstract |
The present invention relates to a new compound for inhibiting binding between a DX2 protein and a p14/ARF protein, and a medical use thereof. A review of the in vitro and in vivo anticancer effect of the compound shows that the compound has an excellent anticancer effect and thus is useful as a drug for treating various cancer diseases including lung cancer, and has a more improved anticancer effect particularly by inhibiting resistance to an anticancer drug of Adriamycin in a cell line which is resistant to an anticancer drug such as Adriamycin, and thus can be used as an anticancer adjuvant for improving the anticancer effect. In addition, the present invention relates to a composition for diagnosing lung cancer comprising an AIMP2-DX2 protein or a fragment thereof, and is effective in diagnosis of lung cancer because whether or not a subject has lung cancer is confirmed only by using a serum sample of the subject. |
| priorityDate |
2014-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |